Guggenheim Capital LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Guggenheim Capital LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $834,042 - $876,276	-5,754 Reduced 21.28%	21,291 $3.22 Million
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $234,953 - $412,567	2,826 Added 11.67%	27,045 $3.94 Million
Q1 2022 May 16, 2022	SELL	$110.08 - $142.92 $19,704 - $25,582	-179 Reduced 0.73%	24,219 $2.87 Million
Q4 2021 Feb 14, 2022	BUY	$99.73 - $148.48 $546,221 - $813,224	5,477 Added 28.95%	24,398 $3.36 Million
Q3 2021 Nov 15, 2021	SELL	$98.85 - $138.91 $507,199 - $712,747	-5,131 Reduced 21.33%	18,921 $2.63 Million
Q2 2021 Aug 13, 2021	SELL	$65.78 - $105.02 $265,948 - $424,595	-4,043 Reduced 14.39%	24,052 $2.34 Million
Q1 2021 May 13, 2021	BUY	$64.07 - $91.75 $148,129 - $212,126	2,312 Added 8.97%	28,095 $1.92 Million
Q4 2020 Feb 16, 2021	BUY	$65.07 - $98.24 $1.68 Million - $2.53 Million	25,783 New	25,783 $2.21 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.